Award
NIH Reporter #2R01FD007632-05
ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman Disease
Recipient
University of Pennsylvania
Award Amount
$600,000.00
Ceiling
$600,000.00
Awarded
September 21, 2026
Identifier
2R01FD007632-05
FDA funding supports continued development of the ACCELERATE Castleman disease registry and research to improve diagnosis, identify clinically meaningful subgroups and treatment-response biomarkers, and evaluate repurposed medications.
Description
Renewal of the FDA award supporting the ACCELERATE international, prospective natural history study of Castleman disease. The project will grow the patient registry, use machine learning and multi-omic and spatial-imaging data to improve diagnosis and identify patient subtypes and treatment-response predictors, and study real-world use of sirolimus and ruxolitinib.